Anavex Life SciencesAVXL -0.74%30 3-Year ROIIC % is -61.60 as of Sep. 2025. GuruFocus rates AVXL with a GF Score™ of 30/100. The stock has 1 warning sign investors should review. Among 1,320 Biotechnology companies, Anavex Life Sciences ranks worse than 66.97% on this metric.
3-Year Return on Invested Incremental Capital (3-Year ROIIC %) measures the change in earnings as a percentage of change in investment over 3-year.
Anavex Life Sciences's 3-Year ROIIC % for the quarter that ended in Sep. 2025 was -61.60%. High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
The industry rank for Anavex Life Sciences's 3-Year ROIIC % or its related term are showing as below:
AVXL's 3-Year ROIIC % is ranked worse than 66.97% of 1320
companies
in the Biotechnology industry
Industry Median: -4.42
vs AVXL: -61.60
Anavex Life Sciences (NAS:AVXL) 3-Year ROIIC % Explanation
Return on Incremental Invested Capital (ROIIC) is an extension of Return on Investment Capital (ROIC). ROIC % tells investors how efficiently that profitability is earned per dollar of company capital. ROIIC narrows the focus even further and shows how profitable each additional unit of capital investment could be. ROIIC % is a more powerful metric than ROIC because it measures how much money the company can generate going forward on future capital investments.
High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
Be Aware
It's important to keep in mind that when tracking ROIIC, the metric is better suited to forecasting the trend of future returns rather than measuring current return on investment.
Anavex Life Sciences 3-Year ROIIC % Related Terms
Anavex Life Sciences 3-Year ROIIC % Historical Data
* Premium members only.
The historical data trend for Anavex Life Sciences's 3-Year ROIIC % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
AVXL vs SLGL, FATE, FHTX: 3-Year ROIIC % Comparison
For the Biotechnology subindustry, Anavex Life Sciences's 3-Year ROIIC %, along with its competitors' market caps and 3-Year ROIIC % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Anavex Life Sciences 3-Year ROIIC % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Anavex Life Sciences's 3-Year ROIIC % distribution charts can be found below:
* The bar in red indicates where Anavex Life Sciences's 3-Year ROIIC % falls into.
Anavex Life Sciences's 3-Year ROIIC % for the quarter that ended in Sep. 2025 is calculated as:
3-Year ROIIC %
=
3-Year Incremental Net Operating Profit After Taxes (NOPAT)**
/
3-Year Incremental Invested Capital**
=
( -51.371 (Sep. 2025) - -50.986 (Sep. 2022) )
/
( 2.367 (Sep. 2025) - 1.742 (Sep. 2022) )
=
-0.38500000000001
/
0.62500000000001
=
-61.60%***
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
** Annual data of NOPAT and Invested Capital was used to calculate 3-Year ROIIC %.
*** Please be aware that the ROIIC (Return on Invested Capital) calculations are based on company-level data using the primary share class. The calculated data provided is for demonstration purposes and may slightly differ from the results displayed in the title due to potential variations caused by currency exchange rate differences throughout the year.
Anavex Life Sciences (AVXL) has a 3-Year ROIIC % of -61.60 as of Sep. 2025. 3-Year ROIIC % measures the change in earnings as a percentage of change in investment over 3-year. View historical data on Anavex Life Sciences and its competitors. According to the industry distribution chart, Anavex Life Sciences ranks #884 out of 1320 companies in the Biotechnology industry, placing it in the top 67%.
Is Anavex Life Sciences' 3-Year ROIIC % too high?
Anavex Life Sciences' current 3-Year ROIIC % is -61.60. Based on the distribution chart, Anavex Life Sciences ranks #884 out of 1320 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Anavex Life Sciences has a GF Score™ of 30/100, reflecting its overall financial health beyond just this single metric.
How does Anavex Life Sciences' 3-Year ROIIC % compare to SLGL and FATE?
According to the Biotechnology industry distribution chart, Anavex Life Sciences ranks #884 out of 1320 companies for 3-Year ROIIC %. This places Anavex Life Sciences in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year ROIIC % for a Biotechnology company?
A good 3-Year ROIIC % depends on the Biotechnology industry context. However, 3-Year ROIIC % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year ROIIC % mean?
A high 3-Year ROIIC % can signal that a stock is expensive relative to its fundamentals. 3-Year ROIIC % measures the change in earnings as a percentage of change in investment over 3-year. View historical data on Anavex Life Sciences and its competitors. Anavex Life Sciences's current 3-Year ROIIC % is -61.60. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Anavex Life Sciences stock overvalued right now?
Anavex Life Sciences (AVXL) has a current 3-Year ROIIC % of -61.60. The current 3-Year ROIIC % is -61.60. Anavex Life Sciences' overall GF Score™ is 30/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year ROIIC % calculated?
3-Year ROIIC % is calculated from a company's financial statements. For Anavex Life Sciences (AVXL), the current 3-Year ROIIC % is -61.60 as of Sep. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Anavex Life Sciences Corp is a clinical stage biopharmaceutical company engaged in the development of differentiated therapeutics by applying precision medicine to central nervous system(CNS) diseases with high unmet need. It analyzes genomic data from clinical trials to identify biomarkers, which are used in the analysis of its clinical trials for the treatment of neurodegenerative and neurodevelopmental diseases. The company focuses on developing treatments for Alzheimer's disease, Parkinson's disease, schizophrenia, neurodevelopmental, neurodegenerative, and rare diseases, including Rett syndrome, and other central nervous system (CNS) disorders. Its pipeline includes ANAVEX 2-73 and ANAVEX 3-71 and several other compounds in different stages of clinical and pre-clinical development.
30GF Score
Get the complete analysis for AVXL
3-Year ROIIC % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
AVXL has been successfully added to your 
